Despite the financial crisis, industrial biotechnology "is taking off," writes The Economist. This sector is doing well, the article says, because the technology has matured beyond the laboratory stage and large corporations are beginning to take advantage of it. Indeed, a few startups that are now being backed by larger firms: Royal Dutch Shell has invested in Codexis and the French oil company Total is backing Amyris. "We're not just dealing with vats any more," says Volkert Claassen of Royal DSM.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.